Telegraph Hill Partners (THP), founded in 2001 and headquartered in San Francisco, California, is a venture capital and growth equity firm specializing in life science, medical technology, and healthcare sectors. The firm focuses on investing in companies that are commercializing advanced technologies in areas such as life science tools, reagents, specialty chemistries, medical devices, diagnostics, healthcare IT, healthcare services, agriculture, and animal health. THP's investment approach is to partner with innovative companies by providing capital and strategic guidance to help them become world-class businesses.

The firm has a history of successful investments, including companies like Althea Technologies, Ambion, Dharmacon, NEXUS Biosystems, LDR, and Vidacare. In 2022, THP raised its largest fund to date, THP V, a $525 million investment fund aimed at supporting innovative companies across the lifecycle from startup to fully scaled. The firm's team consists of experienced venture investors, life science and healthcare experts, M&A professionals, and successful entrepreneurs, working collaboratively to focus on strategy, business development, and operational improvements to create more valuable enterprises.